FDA issues warning for use of mesh in pelvic organ prolapse and urinary incontinence surgery: The FDA is using the database of the Adverse Device Reaction Registry to investigate data between January 1, 2005 and December 31, 2010, which shows that 3,979 injuries, deaths and failures occurred during this period, including seven fatal cases. In response, in July 2011, the FDA issued a warning regarding the use of mesh in pelvic floor prolapse and urinary incontinence surgery, stating that serious complications with transvaginal mesh repair of pelvic organ prolapse are not uncommon and that the use of transvaginal mesh for POP has not been shown to be more effective than traditional surgery. Therefore, the FDA will continue to learn more about the safety and efficacy of the mesh through adverse event reports, epidemiologic investigations, collaboration with professional societies, and post-marketing investigations of the product. This warning has the potential to influence the industry’s choice of surgical approach to pelvic floor prolapse for years to come.